Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Implantica

59.80 SEK+0.34 %28/8 10:00
Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+0.34 %
+1.53 %
-4.63 %
+30.00 %
+19.36 %
-16.25 %
+142.60 %
-45.64 %
-38.07 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
70.76B SEK
Turnover
569.41K SEK
Revenue
22.39M
EBIT %
-990.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Today, RefluxStop has finally received FDA approval, and the company can officially begin its launch in the U.S. market. With this approval, one of the biggest risk factors for this investment has been removed. Today is also the company’s Q2 earnings release, so it will be very interesting...
8/21/2026, 6:01 AM
by Pevitaha
4
Implantica’s RefluxStop® sparked great enthusiasm at the American Foregut Society meeting in the United States ahead of the expected FDA approval. Medtech company Implantica presented its RefluxStop® implant, developed for the treatment of acid reflux, at the AFS annual meeting in...
9/17/2025, 6:49 AM
by Pevitaha
4
Vahva on luotto firmalla, että FDA hyväksyntä tulee, kun on kehitetty uusi tuotantolaite jolla saadaan nopeammin valmistettua RefluxStopia. Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval logo ...
8/13/2025, 6:59 AM
by Pevitaha
3
Based on Q2, Implantica’s European business is moving in the right direction, coinciding with the FDA approval that has opened up the U.S. market. Q2 revenue grew by 66% to €0.717M, and H1 revenue by 34% to €1.574M. The starting level is still low, but the growth rate is promising...
8/21/2026, 6:48 AM
by Pevitaha
2
implantica.com Implantica submits final response to FDA in the PMA application for... Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment...
5/20/2026, 10:03 AM
by Pevitaha
2
Implanticas Q3’25 webcast: Inderes Implantica, Webcast, Q3'25 - Inderes Time: 2025-10-31 15:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference
11/4/2025, 12:40 PM
by Isa Hudd
2
Toinen julkaisu RefluxStopin viiden vuoden seurannan tuloksista. Eihän tässä voi kuin odotella FDA hyväksynnän tuloksia, jotka toivottavasti tulee tässä lähiaikoina (autumn). implantica.com Implantica announces second publication of groundbreaking 5-year results from... Implantica...
8/7/2025, 7:00 AM
by Pevitaha
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19/11
2026

Interim report Q3'26

Press release2026-08-25 08:00

Implantica to host Capital Markets Day in Stockholm on September 9

Implantica
Press release2026-08-25 08:00

Implantica håller kapitalmarknadsdag i Stockholm den 9 september

Implantica
Implantica, Audiocast, Q2'26
Webcast2026-08-21 15:00

Implantica, Audiocast, Q2'26

Implantica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-21 08:00

Implantica publicerar delårsrapport januari - juni 2026 (Q2)

Implantica
Regulatory press release2026-08-21 08:00

Implantica publishes Interim Report January - June 2026 (Q2)

Implantica
Press release2026-08-20 23:36

Investor Studios: Implanticas VD intervjuas i samband med FDA-godkännande

Implantica
Regulatory press release2026-08-20 23:05

Implantica receives FDA approval for RefluxStop® - Opening the U.S. market

Implantica
Regulatory press release2026-08-20 23:05

Implantica erhåller FDA-godkännande för RefluxStop® - öppnar den amerikanska marknaden

Implantica
Press release2026-08-14 10:00

Implantica presents the second quarter (Q2 2026) on August 21 at 15:00 CEST

Implantica
Press release2026-08-14 10:00

Implantica presenterar andra kvartalet (Q2 2026), den 21 augusti kl. 15:00 CEST

Implantica
Regulatory press release2026-06-10 19:50

Bulletin from the Annual General Meeting of Implantica AG

Implantica
Press release2026-06-09 08:00

Implantica tillkännager öppnandet av det 20:e RefluxStop® Center of Excellence i Spanien, som ingår i en världsberömd amerikansk sjukhuskoncern

Implantica
Press release2026-06-09 08:00

Implantica announces launch of 20[th] RefluxStop® Center of Excellence in Spain, part of a world-renowned US hospital group

Implantica
Regulatory press release2026-05-22 08:00

Implantica publicerar delårsrapport januari - mars 2026 (Q1)

Implantica
Regulatory press release2026-05-22 08:00

Implantica publishes Interim Report January - March 2026 (Q1)

Implantica
Regulatory press release2026-05-21 11:00

Notice of Annual General Meeting of Implantica AG

Implantica
Press release2026-05-21 08:00

Implantica tillkännager publiceringen av en ny hälsoekonomisk studie som visar RefluxStop®'s överlägsna kostnadseffektivitet vid behandling av GERD i det italienska sjukvårdssystemet

Implantica
Press release2026-05-21 08:00

Implantica announces publication of a new health economics study showing RefluxStop®'s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

Implantica
Press release2026-05-20 08:00

Implantica submits final response to FDA in the PMA application for RefluxStop® for U.S. market approval

Implantica
Press release2026-05-20 08:00

Implantica lämnar in slutgiltigt svar till FDA gällande PMA-ansökan för RefluxStop® för marknadsgodkännande i USA

Implantica